Malignant Pleural Mesothelioma Clinical Trial
Official title:
EORTC Randomized Phase II Study of Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage Malignant Pleural Mesothelioma
Verified date | November 2022 |
Source | European Organisation for Research and Treatment of Cancer - EORTC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage MPM will be randomized between Arm A: immediate P/D followed by three cycles of chemotherapy (pemetrexed 500mg/m2 and cisplatin 75 mg/m2, both drugs given on day 1, every three weeks) Arm B: three cycles of chemotherapy (same regimen) followed by P/D, for non-progressing patients
Status | Active, not recruiting |
Enrollment | 64 |
Est. completion date | September 2023 |
Est. primary completion date | July 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Patients aged 18 years or older, with pathologically proven malignant pleural mesothelioma. All histological subtypes are accepted. - Stage cT1-3, N0-2, M0 according to UICC TNM classification. FDG-PET-CT scan showing absence of M1, N3, supraclavicular and coeliac node involvement is required. No clinical invasion of mediastinal structures (heart, aorta, spine, esophagus, etc.) and no widespread chest wall invasion (T4) are acceptable. Focal chest wall lesions are acceptable. - No prior treatment of any kind for mesothelioma is allowed, especially prophylactic track irradiation after diagnostic procedures. - WHO performance status 0-1 - Fit to receive chemotherapy and undergo a pleurectomy/ decortication with optional removal of hemidiaphragm and pericardium. - No history of other malignancy within the last three years, except for carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin. - No pre-existing peripheral sensory or motor neuropathy > grade I according to CTCAE v4.0 - No clinically significant pleural effusion that cannot be managed with thoracentesis or pleurodesis (according to institutional practice). If pleurodesis is considered, it should be done before randomization. - Adequate organ function Women of child bearing potential must have a negative serum (or urine) pregnancy test within 3 days prior to the start of chemotherapy/surgery. Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least three months after the last study treatment. Before patient registration written informed consent must be given according to ICH/GCP, and national/local regulations. Exclusion Criteria • Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures, known infection with HIV, active hepatitis B and/or hepatitis C virus). significant cardiovascular morbidity (assessed by cardiologist) precluding surgery - Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery (other than P/D) during the course of study treatment. - History of receiving any investigational treatment within 28 days of randomization. - History of intolerance to pemetrexed and/or cisplatin. - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol. |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Antwerpen | Antwerpen | |
Belgium | UZ Gent | Gent | |
Netherlands | The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis | Amsterdam | |
Netherlands | Erasmus MC Hospital | Rotterdam |
Lead Sponsor | Collaborator |
---|---|
European Organisation for Research and Treatment of Cancer - EORTC |
Belgium, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of success to complete the full treatment | A patient is considered to be a "treatment success" if he/she meets all of the following criteria:
Patient has received the full protocol treatment, defined as 3 cycles of pemetrexed and cisplatin (allowing for the dose adjustments described in section 5.3), preceded/followed by pleurectomy/decortication (P/D) (as described in section 5.3). Patient alive and has no evidence of progression/relapse at week 20 (±2 weeks) after the first day of starting protocol treatment (either chemotherapy or P/D). Patient has no persisting grade 3-4 treatment side-effects (CTCAE V 4.0) at week 20 (±2 weeks) after the first day of starting protocol treatment (either chemotherapy or P/D) |
20weeks | |
Secondary | Loco-regional failure free survival | Loco-Regional Failure Free Survival (LRFFS) is defined as the time interval between the date of randomization and the date of relapse in hemithorax or mediastinum or death, whichever comes first | 6 months | |
Secondary | Overall survival | the time interval between the date of randomization and the date of death of any cause | 15 months | |
Secondary | Treatment side-effects | Treatment side-effects will be assessed for all patients and graded per CTCAE category upon occurrence of the event. The investigator will assess whether those events are surgery or/and drug related (no reasonable possibility, reasonable possibility) and this assessment will be recorded in the database for all adverse events. Surgical side effects during the perioperative period will be scored according to the Clavien-Dindo Classification of Surgical Complications as an exploratory approach. | 36 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06037941 -
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
|
N/A | |
Completed |
NCT01675765 -
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
|
Phase 1 | |
Withdrawn |
NCT04201145 -
Pembrolizumab + Defactinib In Pleural Mesothelioma
|
Phase 1 | |
Completed |
NCT03048474 -
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT02369198 -
MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC
|
Phase 1 | |
Terminated |
NCT01870609 -
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT00886028 -
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT00272558 -
Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT04843007 -
Alvopem® (Pemetrexed) Safety Assessment
|
||
Completed |
NCT01721018 -
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00797719 -
Short Neoadjuvant Hemithoracic IMRT for MPM
|
Phase 1/Phase 2 | |
Completed |
NCT00386815 -
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
Completed |
NCT04775446 -
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
|
||
Completed |
NCT01644994 -
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
|
Phase 1/Phase 2 | |
Completed |
NCT01865045 -
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
|
||
Completed |
NCT00571298 -
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
|
Phase 1 | |
Recruiting |
NCT01343264 -
Trimodality Therapy for Malignant Pleural Mesothelioma
|
N/A | |
Active, not recruiting |
NCT04162015 -
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
|
Phase 1 | |
Recruiting |
NCT04400539 -
The IMmunotherapy Pleural 5-ALA PDT
|
Phase 2 |